Stock listing

NASDAQ:LPCN Lipocine Inc. Stock

Home listing (NASDAQ) of Lipocine Inc.

Follow Lipocine Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:LPCN

$1.48 USD -0.04 (-2.6%)

Close on Nov 20, 2026

Past year -53.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.43 – $1.55 USDNov 20, 2026
Volume
215,726 sharesNov 20, 2026
Market cap
$16.39M USDAt the close on Nov 20, 2026 · price × 11.07M shares outstanding
52-week range
$1.37 – $12.37 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$3.89M USDMedian day 71,956 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Lipocine Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:LPCN · Home$1.48 USD-0.04 (-2.6%)215,726$1.43$1.549$1.43$1.52Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:LPCN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.48-0.04-2.6%$1.43$1.549$1.43215,726
$1.52-0.08-5.0%$1.60$1.62$1.5159,603
$1.60-0.06-3.6%$1.64$1.68$1.5771,956
$1.66-0.05-2.9%$1.71$1.75$1.63126,728
$1.71+0.09+5.6%$1.63$1.75$1.53214,107
$1.62+0.03+1.9%$1.561$1.63$1.5293,267
$1.590.000.0%$1.62$1.64$1.56206,506
$1.59-0.13-7.6%$1.66$1.69$1.56158,543
$1.72+0.15+9.6%$1.597$1.74$1.58259,430
$1.57+0.04+2.6%$1.59$1.63$1.50507,633
$1.53+0.09+6.3%$1.47$1.59$1.406415,968
$1.44-0.02-1.4%$1.50$1.50$1.425101,749
$1.46+0.01+0.7%$1.42$1.50$1.42188,277
$1.45+0.01+0.7%$1.45$1.46$1.365247,846
$1.44-0.08-5.3%$1.50$1.50$1.42111,917
$1.52+0.01+0.7%$1.51$1.559$1.50139,013
$1.51+0.05+3.4%$1.46$1.54$1.46193,298
$1.46+0.01+0.7%$1.49$1.49$1.425127,603
$1.45+0.01+0.7%$1.44$1.45$1.40108,521
$1.44-0.02-1.4%$1.42$1.48$1.41218,100
$1.46-0.14-8.8%$1.56$1.60$1.43354,800
$1.60-0.02-1.2%$1.59$1.64$1.581159,600
$1.62+0.09+5.9%$1.54$1.66$1.537244,700
$1.53-0.03-1.9%$1.51$1.57$1.40323,400
$1.56-0.12-7.1%$1.66$1.68$1.48405,900
$1.68-0.01-0.6%$1.64$1.69$1.59264,400
$1.69+0.07+4.3%$1.69$1.71$1.60374,300
$1.62-0.04-2.4%$1.64$1.74$1.61500,400
$1.66-0.06-3.5%$1.705$1.77$1.59877,600
$1.72-0.21-10.9%$1.89$1.90$1.721,056,700
$1.93-0.27-12.3%$2.05$2.05$1.892,322,300
$2.20+0.10+4.8%$2.95$3.15$2.07105,835,900
$2.10+0.03+1.4%$2.08$2.10$2.0712,800
$2.07+0.02+1.0%$2.07$2.135$2.0719,800
$2.05-0.02-1.0%$2.08$2.13$2.0538,900
$2.07-0.13-5.9%$2.19$2.19$2.0771,200
$2.20+0.04+1.9%$2.14$2.25$2.0831,400
$2.16+0.07+3.3%$2.09$2.21$2.0924,300
$2.09-0.01-0.5%$2.07$2.21$2.0634,400
$2.10+0.01+0.5%$2.12$2.182$2.0632,800
$2.09-0.03-1.4%$2.10$2.178$2.0832,600
$2.12-0.04-1.9%$2.15$2.18$2.1290,900
$2.16-0.08-3.6%$2.13$2.22$2.1264,300
$2.24+0.03+1.4%$2.19$2.25$2.1816,700
$2.21-0.01-0.5%$2.20$2.25$2.1248,500
$2.22+0.06+2.8%$2.16$2.22$2.1043,900
$2.16-0.025-1.1%$2.23$2.235$2.1564,000
$2.185-0.035-1.6%$2.20$2.24$2.1550,500
$2.22-0.05-2.2%$2.20$2.27$2.1527,300
$2.27+0.02+0.9%$2.29$2.30$2.2510,400
$2.250.000.0%$2.315$2.345$2.259,400
$2.25-0.11-4.7%$2.34$2.353$2.254,800
$2.36-0.09-3.7%$2.39$2.40$2.34521,100
$2.45+0.03+1.2%$2.421$2.48$2.36123,100
$2.42+0.065+2.8%$2.41$2.50$2.3226,500
$2.355+0.055+2.4%$2.22$2.39$2.2234,200
$2.30+0.06+2.7%$2.19$2.30$2.18310,000
$2.24+0.07+3.2%$2.14$2.29$2.1427,500
$2.17-0.06-2.7%$2.23$2.23$2.1319,500
$2.23+0.08+3.7%$2.17$2.30$2.1741,500
$2.150.000.0%$2.15$2.29$2.15106,000
$2.15+0.09+4.4%$2.08$2.16$2.0711,800
$2.06-0.03-1.4%$2.07$2.10$2.0526,700
$2.090.000.0%$2.11$2.11$2.0618,200
$2.09+0.04+2.0%$2.05$2.135$2.0535,200

Splits

2 splits since 2013 · NASDAQ:LPCN · every price before a split is adjusted for it

DayRatioWhat
1-for-17Consolidation
1-for-100Consolidation
Ticker
NASDAQ:LPCN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Lipocine Inc. news

Lipocine Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 138 in all · newest Nov 10, 2026 · oldest 2019
Decks
153 decks · latest October 2026

Where Lipocine Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:LPCN · Home listing · This pageNASDAQUnited StatesUSD
BOATS:LPCNBOATSUnited StatesUSD

Valuation

EV/sales −1.4× against a median of 4.7×: the lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$5.07M USD
P/E
Loss
EV/sales
−1.4×
EV/EBITDA
Negative EBITDA
Price/book
0.8×
Gross margin
Not reported
Operating margin
−269.1%
Net margin
−249.2%
Debt to equity
0.0×
Beta vs S&P 500
1.18

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Lipocine Inc. · NASDAQ:LPCNUS$16.39M−US$5.07Mn/a−1.4×n/a0.8×−249.2%0.0×1.18
SynCore Biotechnology Co., Ltd. · TPEX:4192US$16.80MUS$12.38Mn/a15.6×n/a2.5×−178.5%0.0×n/a
Initiator Pharma A/S · OMXSTO:INITUS$16.74MUS$15.65Mn/an/an/a13.4×n/a1.1×n/a
Neurotech International Ltd. · ASX:NTIUS$16.63MUS$15.06Mn/an/an/a41.1×n/a0.0×n/a
Akari Therapeutics PLC · NASDAQ:AKTXUS$16.41MUS$10.66Mn/an/an/a0.9×n/a0.0×1.49
MaaT Pharma · EURONEXT:MAATUS$16.11MUS$23.36Mn/a4.7×n/an/a−686.6%n/an/a
Elicera Therapeutics AB · OMXSTO:ELICUS$16.09MUS$10.40Mn/an/an/a2.9×n/a0.0×n/a
Pasithea Therapeutics Corp. · NASDAQ:KTTAUS$16.00M−US$25.22Mn/an/a−0.1×0.4×n/a0.0×0.97
Atossa Therapeutics, Inc. · NASDAQ:ATOSUS$15.92M−US$4.66Mn/an/an/a0.7×n/a0.0×0.87
Quoin Pharmaceuticals. Ltd · NASDAQ:QNRXUS$15.76M−US$17.43Mn/an/an/a0.6×n/a0.0×0.68
Celularity Inc. · NASDAQ:CELUUS$15.02MUS$50.46Mn/a2.7×n/an/a−117.3%n/a1.47
Median of the othersUS$16.10MUS$11.52M4.7×−0.1×1.7×−178.5%0.0×0.97

Forecasts

1 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
5.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.20 · 1 analyst
Revenue, year to Dec 2026
2.75M · 1 analyst

Team and board

Officers

OfficerRole
Mahesh V. PatelPresident & Chief Executive Officer
Benjamin BrunoVP of Clinical Development
Nachiappan ChidambaramVP Product Development
Anthony DelConteChief Medical Director
Krista FogartyPrincipal Accounting Officer & Corporate Controller

Board

DirectorRole
R. Dana OnoChairman of the Board
Jill M. JeneDirector
John W. HiguchiDirector
Mahesh V. PatelPresident & Chief Executive Officer
Michael GrissingerDirector

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open+6.3%
Q2 2026Aug 4, 2026 · Before open+0.9%
Q1 2026May 7, 2026 · Before open−1.6%
Q4 2025Mar 10, 2026+14.1%
Q3 2025Nov 6, 2025 · Before open+3.1%
Q2 2025Aug 14, 2025 · Before open+0.8%
Q1 2025May 8, 2025 · Before open−2.0%
Q4 2024Mar 5, 2025 · Before open+10.1%
Q3 2024Nov 7, 2024 · Before open−7.8%
Q2 2024Aug 8, 2024 · Before open−12.9%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · Before open+8.0%
Q4 2023Mar 7, 2024 · Before open+1.4%
Q3 2023Nov 8, 2023 · Before open−1.2%
Q2 2023Aug 10, 2023 · Before open−1.6%
Q1 2023May 11, 2023 · Before open+7.1%
Q4 2022Mar 10, 2023 · Before open−26.7%
Q3 2022Nov 9, 2022 · Before open−5.9%
Q2 2022Aug 8, 2022 · Before open−11.1%
Q1 2022May 9, 2022 · Before open−2.2%
Q4 2021Mar 9, 2022 · Before open+6.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck42 slidesOctober 2026
H.C. Wainwright 28th Annual Global Investment Conference 2026Conference22 slidesSeptember 2026
Technical Presentation (June 2026)Technical46 slidesJun 12, 2026
Investor Presentation (May 2026)Investor deck58 slidesMay 7, 2026
ASCP 2026Conference15 slidesMay 2026
Investor Presentation (May 2026)Investor deck59 slidesMay 2026
Investor Presentation (April 2026)Investor deck47 slidesApr 2, 2026
Investor Presentation (April 2026)Investor deck21 slidesApril 2026
Investor Presentation (March 2026)Investor deck8 slidesMarch 2026
Investor Presentation (March 2026)Investor deck4 slidesMarch 2026
Show 50 decks
DeckKindSlidesDate
Investor Presentation (March 2026)Investor deck7 slidesMarch 2026
Investor Presentation (March 2026)Investor deck13 slidesMarch 2026
Investor Presentation (March 2026)Investor deck5 slidesMarch 2026
Investor Presentation (March 2026)Investor deck6 slidesMarch 2026
Investor Presentation (March 2026)Investor deck5 slidesMarch 2026
Investor Presentation (February 2026)Investor deck44 slidesFeb 18, 2026
Investor Presentation (January 2026)Investor deck38 slidesJan 12, 2026
J.P. Morgan Healthcare Conference 2026Conference8 slidesJanuary 2026
Investor Presentation (November 2025)Investor deck47 slidesNov 18, 2025
Investor Presentation (September 2025)Investor deck37 slidesSep 26, 2025
H.C. Wainwright 27th Annual Global Investment Conference 2025Conference25 slidesSep 5, 2025
BIO 2025Conference17 slidesAugust 2025
BIO 2025Conference9 slidesAugust 2025
BIO 2025Conference10 slidesAugust 2025
BIO 2025Conference13 slidesAugust 2025
Technical Presentation (July 2025)Technical42 slidesJul 9, 2025
Investor Presentation (July 2025)Investor deck60 slidesJuly 2025
Bio International Convention 2025Conference17 slidesJune 2025
Investor Presentation (May 2025)Investor deck58 slidesMay 12, 2025
Investor Presentation (May 2025)Investor deck28 slidesMay 2025
Investor Presentation (May 2025)Investor deck9 slidesMay 2025
BIO 2025Conference9 slidesMay 2025
BIO 2025Conference9 slidesMay 2025
Investor Presentation (April 2025)Investor deck54 slidesApr 3, 2025
Investor Presentation (February 2025)Investor deck47 slidesFeb 11, 2025
Investor Presentation (January 2025)Investor deck46 slidesJan 13, 2025
Investor Presentation (December 2024)Investor deck45 slidesDec 13, 2024
Technical Presentation (October 2024)Technical35 slidesOct 16, 2024
H.C. Wainwright 5th Annual MASH Investor Conference 2024Conference22 slidesOct 8, 2024
EASL Congress (June 2024)Conference24 slidesJun 10, 2024
Investor Presentation (April 2024)Investor deck43 slidesApr 29, 2024
Technical Presentation (April 2024)Technical18 slidesApr 11, 2024
Investor Presentation (March 2024)Investor deck41 slidesMar 7, 2024
Investor Presentation (January 2024)Investor deck29 slidesJan 9, 2024
Biotech Showcase 2024Conference8 slides2024
EASL Congress 2024Conference24 slides2024
Technical Presentation (November 2023)Technical22 slidesNov 13, 2023
Investor Presentation (October 2023)Investor deck28 slidesOct 24, 2023
Technical Presentation (July 2023)Technical21 slidesJul 27, 2023
Investor Presentation (June 2023)Investor deck36 slidesJun 26, 2023

This page holds 50 of 153 decks. Open Decks

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.98M11.2M-2.85M500.0K16.1M0165.0K428.0K00
Cost of revenue8.58M41.1K10.2M8.56M7.67M9.75M7.47M6.46M11.0M8.08M
Gross profit-6.61M11.2M-13.0M-8.06M8.48M-9.75M-7.30M428.0K-11.0M-8.08M
Research and development8.58M7.35M10.2M8.56M7.67M9.75M7.47M6.46M11.0M8.08M
Selling, general and administrative3.76M5.00M4.90M4.06M5.33M8.25M5.60M5.29M10.2M10.4M
Operating income-10.4M-1.16M-17.9M-12.1M3.15M-18.0M-12.9M-11.3M-21.2M-19.2M
Depreciation and amortization60.8K41.1K28.7K9.45K3803.55K15.4K18.6K28.4K32.0K
EBITDA-10.3M-1.11M-17.9M-12.1M3.15M-18.0M-12.9M-11.3M-21.2M-19.2M
Interest expense027.1K203.3K386.6K766.7K000
Income before tax-9.63M9.03K-16.4M-10.8M-634.2K-21.0M-13.0M-11.7M-21.0M-19.0M
Income tax200681755681200200200700700752
Net income-9.63M8.35K-16.4M-10.8M-634.4K-21.0M-13.0M-11.7M-21.0M-19.0M
Earnings per share, basic-1.770.00-3.10-2.06-0.01-0.38-0.50-0.55-1.05-1.04
Earnings per share, diluted-1.69-3.14-2.15-0.01-0.38-0.50-0.55-1.05-1.04

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents5.21M6.21M4.77M3.15M2.95M19.2M9.73M8.08M3.21M5.56M
Short-term investments9.72M15.4M17.3M29.4M41.7M450.0K4.34M7.17M18.3M21.3M
Receivables14.2K120.4K52.3K659.9K247.3K39116.5K38.5K3.34M38.9K
Inventory1-41.9M5.00M5.00M00
Current assets16.9M22.3M22.9M34.1M46.4M25.3M19.6M20.8M25.2M27.2M
Property, plant and equipment104.3K165.1K116.1K131.6K7.21K3.55K19.0K75.1K103.4K
Goodwill00
Total assets17.0M22.5M23.0M37.5M52.5M25.4M19.7M20.9M25.3M27.3M
Accounts payable971.8K271.7K1.40M600.4K1.29M1.60M1.18M671.3K598.1K245.9K
Current liabilities2.53M1.51M2.63M1.68M5.62M6.58M4.96M4.49M6.35M1.33M
Long-term debt2.26M3.81M6.93M00
Total debt449.6K438.6K17.2K1.67M5.00M6.67M10.0M0
Total liabilities2.53M1.51M2.63M1.91M6.91M10.0M13.4M11.4M6.35M1.33M
Shareholders' equity14.5M21.0M20.4M35.6M45.6M15.3M6.29M9.43M19.0M26.0M
Shares outstanding6.16M5.35M5.32M5.23M88.3M70.0M37.6M21.7M21.3M18.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-9.76M-1.22M-11.9M-12.0M-4.41M-15.3M-11.7M-12.1M-16.7M-18.3M
Capital spending-1-90.1K-13.2K-133.8K-7.59K-7.59K-7.59K00-59.6K
Free cash flow-9.76M-1.31M-11.9M-12.1M-4.42M-15.3M-11.7M-12.1M-16.7M-18.3M
Cash from investing5.89M2.45M13.1M14.3M-43.8M3.89M3.00M11.3M3.13M3.23M
Cash from financing2.87M209.3K404.6K-2.13M26.9M20.9M10.3M10.7M11.2M605.9K
Dividends paid-211.4K00
Share buybacks-21.7K26.9M13.3M13.7M652.3K581.1K605.9K
Change in cash-1.00M1.43M1.62M197.9K-21.3M9.49M1.65M9.87M-2.35M-14.4M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 20, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
8-K · Current reportNov 10, 2026Current reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportOct 20, 2026Current reportSEC
8-K · Current reportOct 7, 2026Current reportSEC
4 · Change in ownershipOct 1, 2026Insider tradeSEC
4 · Change in ownershipSep 30, 2026Insider tradeSEC
8-K · Current reportSep 16, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportSep 14, 2026Current reportSEC
8-K · Current reportSep 11, 2026Current reportSEC
8-K · Current reportSep 10, 2026Current reportSEC
8-K/A · Current report, amendedAug 21, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 7, 2026Insider tradeSEC
8-K · Current reportAug 4, 2026ResultsSEC
10-Q · Quarterly reportAug 4, 2026Quarterly reportSEC
8-K · Current reportAug 3, 2026Management or board changeSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
8-K · Current reportJun 12, 2026Current reportSEC
S-8 · Registration statement for employee plansJun 9, 2026Offer documentSEC
8-K · Current reportJun 4, 2026Management or board changeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
8-K · Current reportJun 4, 2026Current reportSEC
8-K · Current reportMay 26, 2026Current reportSEC
8-K · Current reportMay 19, 2026Current reportSEC
8-K · Current reportMay 18, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
8-K · Current reportMay 7, 2026Current reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
DEFA14A · Additional proxy materialApr 21, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 21, 2026Meeting noticeSEC
8-K · Current reportApr 21, 2026Management or board changeSEC
4 · Change in ownershipApr 7, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
8-K · Current reportApr 2, 2026Current reportSEC
8-K · Current reportApr 2, 2026Current reportSEC
8-K · Current reportMar 10, 2026ResultsSEC
10-K · Annual reportMar 9, 2026Annual reportSEC
8-K · Current reportMar 4, 2026Current reportSEC
424B5 · ProspectusFeb 26, 2026Offer documentSEC
8-K · Current reportFeb 18, 2026Current reportSEC
8-K · Current reportFeb 18, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
8-K · Current reportJan 20, 2026Current reportSEC
8-K · Current reportJan 12, 2026Current reportSEC
8-K · Current reportJan 12, 2026Current reportSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeDec 23, 2025Big-stake noticeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
8-K · Current reportDec 16, 2025Current reportSEC
8-K · Current reportDec 15, 2025Management or board changeSEC
8-K · Current reportDec 11, 2025Current reportSEC
8-K · Current reportNov 18, 2025Current reportSEC
8-K · Current reportNov 18, 2025Current reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 4, 2025Current reportSEC
8-K · Current reportSep 30, 2025Current reportSEC
8-K · Current reportSep 26, 2025Current reportSEC
8-K · Current reportSep 5, 2025Current reportSEC
8-K · Current reportSep 5, 2025Current reportSEC
8-K · Current reportAug 26, 2025Current reportSEC
8-K · Current reportAug 5, 2025ResultsSEC
10-Q · Quarterly reportAug 5, 2025Quarterly reportSEC
8-K · Current reportJul 9, 2025Current reportSEC
8-K · Current reportJul 2, 2025Current reportSEC
8-K · Current reportJun 26, 2025Current reportSEC
8-K · Current reportJun 23, 2025Current reportSEC
8-K · Current reportJun 9, 2025Current reportSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
8-K · Current reportJun 4, 2025Meeting outcomeSEC
8-K · Current reportMay 22, 2025Current reportSEC
8-K · Current reportMay 14, 2025Current reportSEC
8-K · Current reportMay 12, 2025Current reportSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025Current reportSEC
8-K · Current reportMay 6, 2025Current reportSEC
DEF 14A · Proxy statementApr 22, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 10, 2025Meeting noticeSEC
8-K · Current reportApr 3, 2025Current reportSEC
8-K · Current reportMar 26, 2025Current reportSEC
8-K · Current reportMar 13, 2025Current reportSEC
10-K · Annual reportMar 13, 2025Annual reportSEC
8-K · Current reportMar 12, 2025Current reportSEC
8-K · Current reportFeb 11, 2025Current reportSEC
8-K · Current reportFeb 6, 2025Current reportSEC
8-K · Current reportJan 13, 2025Current reportSEC
4/A · Change in ownership, amendedJan 2, 2025Insider tradeSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2024Insider tradeSEC
4 · Change in ownershipDec 30, 2024Insider tradeSEC
8-K · Current reportDec 17, 2024Current reportSEC
8-K · Current reportDec 13, 2024Current reportSEC
8-K · Current reportNov 18, 2024Current reportSEC
8-K · Current reportNov 7, 2024Current reportSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 5, 2024Current reportSEC
8-K · Current reportOct 31, 2024Current reportSEC
8-K · Current reportOct 22, 2024Material contractSEC
8-K · Current reportOct 16, 2024Current reportSEC
8-K · Current reportOct 10, 2024Current reportSEC
8-K · Current reportOct 8, 2024Current reportSEC
8-K · Current reportOct 7, 2024Current reportSEC
8-K · Current reportOct 2, 2024Current reportSEC
8-K · Current reportSep 30, 2024Current reportSEC
8-K · Current reportSep 5, 2024Current reportSEC
8-K · Current reportAug 27, 2024Current reportSEC
8-K · Current reportAug 8, 2024Current reportSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K/A · Current report, amendedAug 7, 2024Meeting outcomeSEC
8-K · Current reportJun 25, 2024Current reportSEC
8-K · Current reportJun 10, 2024Current reportSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
8-K · Current reportJun 5, 2024Meeting outcomeSEC
8-K · Current reportJun 3, 2024Management or board changeSEC
DEFA14A · Additional proxy materialJun 3, 2024Meeting noticeSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024Current reportSEC
8-K · Current reportMay 8, 2024Current reportSEC
8-K · Current reportMay 1, 2024Current reportSEC
8-K · Current reportApr 29, 2024Current reportSEC
8-K · Current reportApr 26, 2024Material contractSEC
424B5 · ProspectusApr 26, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 26, 2024Other filingsSEC
CORRESP · Letter to the SECApr 24, 2024Other filingsSEC
S-3/A · Registration statement, amendedApr 23, 2024Offer documentSEC
DEF 14A · Proxy statementApr 23, 2024Meeting noticeSEC
8-K · Current reportApr 11, 2024Current reportSEC
8-K · Current reportMar 28, 2024Current reportSEC
8-K · Current reportMar 25, 2024Current reportSEC
4 · Change in ownershipMar 12, 2024Insider tradeSEC
4 · Change in ownershipMar 12, 2024Insider tradeSEC
8-K · Current reportMar 7, 2024Current reportSEC
8-K · Current reportMar 7, 2024ResultsSEC
10-K · Annual reportMar 7, 2024Annual reportSEC
8-K · Current reportMar 6, 2024Current reportSEC
8-K · Current reportFeb 12, 2024Current reportSEC
8-K · Current reportJan 18, 2024Material contractSEC
8-K · Current reportJan 8, 2024Current reportSEC
8-K · Current reportDec 19, 2023Current reportSEC
UPLOAD · Letter from the SECNov 29, 2023Other filingsSEC
S-3 · Registration statementNov 22, 2023Offer documentSEC
8-K · Current reportNov 13, 2023Current reportSEC
10-Q · Quarterly reportNov 8, 2023Quarterly reportSEC
8-K · Current reportNov 8, 2023Current reportSEC
8-K · Current reportNov 1, 2023Current reportSEC
8-K · Current reportOct 26, 2023Current reportSEC
8-K · Current reportOct 23, 2023Current reportSEC
8-K · Current reportOct 6, 2023Current reportSEC
8-K · Current reportSep 19, 2023Current reportSEC
8-K · Current reportAug 10, 2023Current reportSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
8-K · Current reportJul 27, 2023Current reportSEC
8-K · Current reportJun 26, 2023Current reportSEC
8-K · Current reportJun 26, 2023Current reportSEC
8-K · Current reportJun 23, 2023Current reportSEC
8-K · Current reportJun 14, 2023Current reportSEC
8-K · Current reportJun 7, 2023Current reportSEC
8-K · Current reportMay 31, 2023Current reportSEC
4 · Change in ownershipMay 25, 2023Insider tradeSEC
8-K · Current reportMay 16, 2023Current reportSEC
4 · Change in ownershipMay 12, 2023Insider tradeSEC
4 · Change in ownershipMay 12, 2023Insider tradeSEC
4 · Change in ownershipMay 12, 2023Insider tradeSEC
4 · Change in ownershipMay 12, 2023Insider tradeSEC
4 · Change in ownershipMay 12, 2023Insider tradeSEC
8-K · Current reportMay 11, 2023Meeting outcomeSEC
8-K · Current reportMay 11, 2023Current reportSEC
10-Q · Quarterly reportMay 11, 2023Quarterly reportSEC
8-K · Current reportMay 5, 2023Current reportSEC
424B5 · ProspectusApr 3, 2023Offer documentSEC
8-K · Current reportApr 3, 2023Management or board changeSEC
DEF 14A · Proxy statementMar 27, 2023Meeting noticeSEC
4 · Change in ownershipMar 24, 2023Insider tradeSEC
4 · Change in ownershipMar 20, 2023Insider tradeSEC
ARS · Annual report to shareholdersMar 20, 2023Annual reportSEC
4 · Change in ownershipMar 17, 2023Insider tradeSEC
PRE 14A · Preliminary proxy statementMar 17, 2023Meeting noticeSEC
8-K · Current reportMar 13, 2023Current reportSEC
10-K · Annual reportMar 10, 2023Annual reportSEC
8-K · Current reportMar 10, 2023Current reportSEC
8-K · Current reportMar 10, 2023Current reportSEC

This page holds 200 of 826 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Lipocine Inc.’s releases · as of Nov 4, 2026

Common shares
11,073,439
Fully diluted
11,073,439

Fully diluted

LineSharesAs of
Common shares11,073,439Nov 4, 2026

Share count over time

CountShares
Nov 4, 202611,073,439

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Squadron Capital Management LLC810K7.3%US$1.78MSep 30, 2026
Ikarian Capital, LLC509K4.6%US$1.12MSep 30, 2026
Eversept Partners, LP294K2.7%US$646KSep 30, 2026
Vanguard287K2.6%US$632KSep 30, 2026
Acadian Asset Management LLC170K1.5%US$373KSep 30, 2026
Boothbay Fund Management, LLC140K1.3%US$309KSep 30, 2026
BlackRock89,2720.81%US$196KSep 30, 2026
Citadel77,6770.70%US$171KSep 30, 2026
Two Sigma77,4070.70%US$170KSep 30, 2026
Geode Capital75,0140.68%US$165KSep 30, 2026
All 36 holders
HolderSharesOf the companyValueAs of
Renaissance Technologies70,2840.63%US$155KSep 30, 2026
Susquehanna48,7940.44%US$107KSep 30, 2026
Jane Street39,9200.36%US$87,824Sep 30, 2026
Dimensional38,0030.34%US$83,607Sep 30, 2026
Seven Fleet Capital Management LP34,1610.31%US$75,154Sep 30, 2026
State Street22,4070.20%US$49,295Sep 30, 2026
Gsa Capital Partners LLP18,6660.17%US$41,000Sep 30, 2026
Birchview Capital, LP16,7120.15%US$36,766Sep 30, 2026
Northern Trust15,9420.14%US$35,072Sep 30, 2026
XTX Topco Ltd15,8980.14%US$34,976Sep 30, 2026
T. Rowe Price12,2660.11%US$27,000Sep 30, 2026
Hrt Financial LP11,0630.10%US$24,000Sep 30, 2026
Barclays9,4150.09%US$20,713Sep 30, 2026
UBS3,4570.03%US$7,605Sep 30, 2026
Citigroup Inc2,0040.02%US$4,409Sep 30, 2026
Wells Fargo2,0000.02%US$4,400Sep 30, 2026
BFC Planning, Inc.1,3240.01%US$2,913Sep 30, 2026
Tower Research Capital LLC (TRC)1,055<0.01%US$2,321Sep 30, 2026
Morgan Stanley574<0.01%US$1,263Sep 30, 2026
Caldwell Sutter Capital, Inc.471<0.01%US$1,036Sep 30, 2026
Osaic Holdings, Inc.266<0.01%US$579Sep 30, 2026
Group One Trading LLC132<0.01%US$290Sep 30, 2026
PlanVest Financial, Inc111<0.01%US$244Sep 30, 2026
SBI Securities Co., Ltd.67<0.01%US$147Sep 30, 2026
Tidemark, LLC59<0.01%US$130Sep 30, 2026
Bogart Wealth, LLC3<0.01%US$7Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund143K1.3%US$365KJun 30, 2026
Vanguard Extended Market Index Fund57,8950.52%US$148KJun 30, 2026
Fidelity Extended Market Index Fund29,7740.27%US$66,992May 31, 2026
Fidelity Total Market Index Fund8,6880.08%US$19,548May 31, 2026
Fidelity Series Total Market Index Fund8,2900.07%US$18,653May 31, 2026
Tiff Multi-Asset Fund6,2010.06%US$15,875Jun 30, 2026
U.S. Sustainability Core 1 Portfolio6,1810.06%US$13,104Jul 31, 2026
Dimensional U.S. Small Cap ETF6,0380.05%US$12,801Jul 31, 2026
Dimensional US Core Equity 1 ETF5,1160.05%US$10,846Jul 31, 2026
U.S. Micro Cap Portfolio5,0400.05%US$10,685Jul 31, 2026
All 16 holders
HolderSharesOf the companyValueAs of
Dimensional U.S. Core Equity 2 ETF4,7600.04%US$10,091Jul 31, 2026
Fidelity Nasdaq Composite Index Fund4,4610.04%US$10,037May 31, 2026
Schwab Total Stock Market Index Fund2,9420.03%US$6,237Jul 31, 2026
U.S. Social Core Equity 2 Portfolio2,7300.02%US$5,788Jul 31, 2026
U.S. Vector Equity Portfolio2,1560.02%US$4,571Jul 31, 2026
U.S. Core Equity 2 Portfolio32<0.01%US$68Jul 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Higuchi John W.
Director
Buy75,000USD 1.49US$112KNov 20, 2026
Higuchi John W.
Director
Buy75,000USD 1.51US$113KNov 19, 2026
Patel Mahesh V.
Director, Officer: Chief Executive Officer
Buy25,000USD 1.60US$39,998Nov 13, 2026
Patel Mahesh V.
Director, Officer: Chief Executive Officer
Buy25,000USD 1.58US$39,490Nov 12, 2026
Higuchi John W.
Director
Buy15,970USD 2.23US$35,613Sep 30, 2026
Higuchi John W.
Director
Buy9,037USD 2.15US$19,430Sep 29, 2026
Higuchi John W.
Director
Buy12,561USD 2.16US$27,132Sep 28, 2026
Higuchi John W.
Director
Buy40,000USD 2.03US$81,200Apr 7, 2026
Patel Mahesh V.
Director, Officer: Chief Executive Officer
Buy25,000USD 2.03US$50,750Apr 6, 2026
Higuchi John W.
Director
Buy123,000USD 2.05US$252KApr 6, 2026
All 11 trades
TradeTradeSharesPriceValueDate
Patel Mahesh V.
Director, Officer: Chief Executive Officer
Buy25,000USD 2.02US$50,500Apr 2, 2026

Big stakes

StakeStakeSharesDateFiling
Squadron Capital Management LLC9.80%810KJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Spyros Papapetropoulos
Other companies: Neuphoria Therapeutics Inc. (President and CEO, Director · Since at least Jul 1, 2024); Vigil Neuroscience Inc (Chief Medical Officer · Jan 6, 2022 – Nov 18, 2022 · Past); Adamas Pharmaceuticals Inc (Director · Nov 22, 2020 – Nov 24, 2021 · Past)
Director · Since at least Apr 11, 2022
Jyrki Mattila
Other companies: BioSpecifics Technologies Corp (Director · Mar 15, 2018 – May 22, 2019 · Past); Recro Pharma Inc (Executive VP, Business Dev. · Aug 21, 2017 – Jan 2, 2018 · Past)
Chief Business Officer · Jan 5, 2016 – Jan 26, 2017 · Past
Anthony DelConteChief Medical Director · Since at least Nov 5, 2026
Benjamin BrunoVP of Clinical Development · Since at least Jun 4, 2026
Jeffrey Arvin FinkDirector · Since at least Jun 12, 2019
Jill M. JeneDirector · Since at least Jun 4, 2025
John W. HiguchiDirector · Since at least Oct 1, 2026
Krista FogartyPrincipal Accounting Officer · Since at least Jan 19, 2022
Mahesh V. PatelChief Executive Officer, Director · Since at least Apr 2, 2026
Michael GrissingerDirector · Since at least Aug 3, 2026
All 12 people
PersonSeat
Nachiappan ChidambaramVP Product Development · Since at least Nov 5, 2026
R. Dana OnoChairman of the Board · Since at least Aug 3, 2026

Open People

Log in to ask 6ix AI your own questions about Lipocine Inc.